These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 30547287)

  • 1. Measurement of IL-17AA and IL-17FF as Pharmacodynamic Biomarkers to Demonstrate Target Engagement in the Phase I Study of MCAF5352A.
    Peng K; Wang Y; Siradze K; Erickson R; Fischer SK; Staton TL
    AAPS J; 2018 Dec; 21(1):9. PubMed ID: 30547287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of heterophilic antibody blocking agents in reducing false positive interference in immunoassays for IL-17AA, IL-17FF, and IL-17AF.
    DeForge LE; Loyet KM; Delarosa D; Chinn J; Zamanian F; Chuntharapai A; Lee J; Hass P; Wei N; Townsend MJ; Wang J; Wong WL
    J Immunol Methods; 2010 Oct; 362(1-2):70-81. PubMed ID: 20833179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of IL-17AA and IL-17FF in rheumatoid arthritis and multiple sclerosis.
    Schofield C; Fischer SK; Townsend MJ; Mosesova S; Peng K; Setiadi AF; Song A; Baruch A
    Bioanalysis; 2016 Nov; 8(22):2317-2327. PubMed ID: 27620302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformational dynamics in interleukin 17A and 17F functional complexes is a key determinant of receptor A affinity and specificity.
    Waters LC; Veverka V; Strong SL; Muskett FW; Dedi N; Lawson ADG; Prosser CE; Taylor RJ; Henry AJ; Carr MD
    Cytokine; 2021 Jun; 142():155476. PubMed ID: 33706174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers.
    Staton TL; Peng K; Owen R; Choy DF; Cabanski CR; Fong A; Brunstein F; Alatsis KR; Chen H
    BMC Pulm Med; 2019 Jan; 19(1):5. PubMed ID: 30616547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic and pharmacodynamic analysis of BIIB023, an anti-TNF-like weak inducer of apoptosis (anti-TWEAK) monoclonal antibody.
    Galluppi GR; Wisniacki N; Stebbins C
    Br J Clin Pharmacol; 2016 Jul; 82(1):118-28. PubMed ID: 26896828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatoid arthritis bone marrow environment supports Th17 response.
    Kuca-Warnawin E; Kurowska W; Prochorec-Sobieszek M; Radzikowska A; Burakowski T; Skalska U; Massalska M; Plebańczyk M; Małdyk-Nowakowska B; Słowińska I; Gasik R; Maśliński W
    Arthritis Res Ther; 2017 Dec; 19(1):274. PubMed ID: 29216915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
    Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
    J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.
    Wisniacki N; Amaravadi L; Galluppi GR; Zheng TS; Zhang R; Kong J; Burkly LC
    Clin Ther; 2013 Aug; 35(8):1137-49. PubMed ID: 23928094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant Circulating Th17 Cells in Patients with B-Cell Non-Hodgkin's Lymphoma.
    Lu T; Yu S; Liu Y; Yin C; Ye J; Liu Z; Ma D; Ji C
    PLoS One; 2016; 11(1):e0148044. PubMed ID: 26812681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of novel ultra-sensitive IL-11 target engagement assays to support mechanistic PK/PD modeling for an anti-IL-11 antibody therapeutic.
    Myzithras M; Lin S; Radden L; Hess Kenny C; Cai Z; MacDonald A; Binetti R; Marlow M; Fracasso P; Gibson G; Bartlett C; Hawkins J; Hansel S
    MAbs; 2022; 14(1):2104153. PubMed ID: 35916739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.
    Glatt S; Baeten D; Baker T; Griffiths M; Ionescu L; Lawson ADG; Maroof A; Oliver R; Popa S; Strimenopoulou F; Vajjah P; Watling MIL; Yeremenko N; Miossec P; Shaw S
    Ann Rheum Dis; 2018 Apr; 77(4):523-532. PubMed ID: 29275332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cedirogant Population Pharmacokinetics and Pharmacodynamic Analyses of Interleukin-17A Inhibition in Two Phase 1 Studies in Healthy Participants and Participants with Moderate to Severe Psoriasis.
    Maier CS; Eckert D; Laroux FS; Hew KM; Suleiman AA; Liu W; Mohamed MF
    Clin Pharmacol Drug Dev; 2024 May; 13(5):474-484. PubMed ID: 38231873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
    Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
    J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low baseline interleukin-17A levels are associated with better treatment response at 12 weeks to tocilizumab therapy in rheumatoid arthritis patients.
    Lee SJ; Park W; Park SH; Shim SC; Baek HJ; Yoo DH; Kim HA; Lee SK; Leee YJ; Park YE; Cha HS; Park JK; Lee EY; Lee EB; Song YW
    J Immunol Res; 2015; 2015():487230. PubMed ID: 25922848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
    Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.
    Van Roy M; Ververken C; Beirnaert E; Hoefman S; Kolkman J; Vierboom M; Breedveld E; 't Hart B; Poelmans S; Bontinck L; Hemeryck A; Jacobs S; Baumeister J; Ulrichts H
    Arthritis Res Ther; 2015 May; 17(1):135. PubMed ID: 25994180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The bispecific antibody aimed at the vicious circle of IL-1β and IL-17A, is beneficial for the collagen-induced rheumatoid arthritis of mice through NF-κB signaling pathway.
    Wu Q; Wang Y; Wang Q; Yu D; Wang Y; Song L; Liu Z; Ye X; Xu P; Cao H; Li D; Ren G
    Immunol Lett; 2016 Nov; 179():68-79. PubMed ID: 27616043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultra-Sensitive Measurement of IL-17A and IL-17F in Psoriasis Patient Serum and Skin.
    Soderstrom C; Berstein G; Zhang W; Valdez H; Fitz L; Kuhn M; Fraser S
    AAPS J; 2017 Jul; 19(4):1218-1222. PubMed ID: 28534291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leucine-rich α2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis.
    Fujimoto M; Serada S; Suzuki K; Nishikawa A; Ogata A; Nanki T; Hattori K; Kohsaka H; Miyasaka N; Takeuchi T; Naka T
    Arthritis Rheumatol; 2015 May; 67(8):2056-60. PubMed ID: 25917892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.